Welke medicijnen kunnen helpen bij Tinnitus?
Geen enkel medicijn vermindert het tinnitusgeluid. Soms wordt wel medicatie (Seresta of Rivotril) voorgeschreven om de emotionele reactie op tinnitus te beinvloeden, bijvoorbeeld bij angst- of depressieve gevoelens.
Tinnitus oorsuizen medicijn Lijst
www.mijnmedicijn.nl/epilepsie/Rivotril - Clonazepam/tinnitus
Medecijn die Tinnitus Oorsuizen geven
- Anxiolyse, alle Anxiolyse geven oorsuizen
- Seresta, Rivotril, oxazepam, lorazepam,
Pantoprazol geef of versterkt oorsuizen weet iedereen
----------------------------------------------------------------------------------------------------------------------------
https://pdf.hres.ca/dpd_pm/00065938.PDF
Candesartan Cilexetil
Less Common Clinical Trial Adverse Drug Reactions (< 1%) Hypertension
The following AEs were reported at an incidence of <1% in controlled clinical trials (in > 1 patient, with higher frequency than placebo):
Body as a Whole: allergy, asthenia, pain, syncope.
Cardiovascular: angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction,
peripheral ischemia, thrombophlebitis.
Central and Peripheral Nervous System: hypertonia, hypoesthesia, paresthesia, vertigo.
Gastrointestinal: constipation, dry mouth, dyspepsia, toothache.
Hearing: tinnitus.
Metabolic and Nutritional: diabetes mellitus, hyperkalemia, hyponatremia.
Musculoskeletal: arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder.
Blood: anemia, epistaxis.
Psychiatric: depression, impotence, neurosis.
Reproductive: menopausal symptoms.
Resistance Mechanism: otitis.
Respiratory: laryngitis.
Skin: eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria.
Urinary: abnormal urine, cystitis.
Vision: conjunctivitis.
AEs reported at a rate > 1% but at about the same or greater incidence in patients receiving
placebo, in studies using daily doses > 16 mg: albuminuria, arthralgia, chest pain and sinusitis.
Other AEs reported at an incidence of ≥ 0.5% from > 3200 patients treated worldwide include
anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia,
hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia.
Heart Failure
The following listed AEs occurred in < 1% of patients treated with candesartan cilexetil but in
≥ 2 patients and with more frequent occurrence in the candesartan cilexetil group than in the
placebo group (CHARM-Alternative and CHARM-Added).
Skin and Appendages Disorders: angioedema, pruritus, rash
Liver and Biliary System Disorders: hepatic function abnormal
White Cell and Resistance Disorders: granulocytopenia, leukopenia
Abnormal Hematologic and Clinical Chemistry Findings
Laboratory Test Findings
Hypertension
In controlled clinical trials, clinically important changes in standard laboratory parameters were
rarely associated with administration of candesartan cilexetil.
Liver Function Tests: In controlled clinical trials, elevations of AST and ALT (> 3x the upper
limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with candesartan
cilexetil monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo.
Serum Potassium: A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive
patients treated with candesartan cilexetil alone but was rarely of clinical importance. Creatinine, Blood Urea Nitrogen, and Sodium: Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed.
Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with candesartan cilexetil alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials.
Hyperuricemia: Hyperuricemia was rarely found (0.6% of patients treated with candesartan cilexetil and 0.5% of patients treated with placebo).
Heart Failure
Increases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed.
Post-Market Adverse Drug Reactions
In post-marketing experience, the following have been reported in patients treated with candesartan cilexetil:
Blood and lymphatic disorders: thrombocytopenia
Cardiac disorders: atrial fibrillation, bradycardia, cardiac failure, palpitations Digestive: abnormal hepatic function and hepatitis
Gastrointestinal disorders: pancreatitis
General disorders and administration site conditions: chest pain, malaise, sudden death Hematologic: agranulocytosis, leukopenia and neutropenia Immunologic: angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity Infections and infestations: pneumonia
Investigations: blood creatinine increased, fall
Metabolic and Nutritional Disorders: hyperkalemia and hyponatremia Musculoskeletal System: muscle pain, muscle weakness, myositis and rhabdomyolysis Nervous system disorders: cerebrovascular accident, loss of consciousness, presyncope Psychiatric disorders: confusional state
Respiratory System Disorders: cough, pulmonary edema Skin and Appendages Disorders: pruritus, rash and urticarial Urogenital System: renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, Renal, Renal Impairment for definition of susceptible patients)
====================================================================
Reacties